RYZB

Rayze Bio

RayzeBio develops targeted radiopharmaceutical therapies using alpha-emitting isotopes to treat patients with solid tumours and other cancers.

Nuclidium

This clinical-stage company develops copper-based radiopharmaceuticals for the diagnosis and treatment of cancer patients.

LYEL

This company develops engineered cell therapies to treat patients with solid tumours and blood cancers.

Ariceum Therapeutics

This clinical-stage biotechnology company develops targeted radiopharmaceutical therapies for the diagnosis and treatment of aggressive, hard-to-treat cancers.

Cereius

This company develops targeted radiopharmaceuticals and radiodiagnostics for cancer patients, focusing on the treatment of solid tumour brain metastases.

Full-Life Technologies

This company develops radiopharmaceuticals and radionuclide drug conjugates to treat cancer patients through targeted alpha therapy.

Akiram Therapeutics

This biotech company develops targeted radiopharmaceuticals and radioimmunotherapies for patients with solid tumours and metastatic cancers.

Alpha-9 Theranostics

This clinical-stage biotechnology company develops targeted radiopharmaceuticals to treat cancer patients by delivering radiation directly to tumours while sparing healthy tissue.